BCR-ABL directed immunotherapy: A virtual reality?

Leukemia and Lymphoma

Volumn 38, Issue 1-2, 2000, Pages 175-181

  Leeksma, O C ^a   Kessler, J H ^a   Huijbers, I J G ^a   Ten Bosch, G J A ^a   Melief, C J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BCR ABL; HLA; Junctional region peptides; T cells

Indexed keywords

HLA ANTIGEN; HYBRID PROTEIN; ONCOPROTEIN;

ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; LEUKEMIA; PRIORITY JOURNAL;

EID: 0034052906     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009060331     Document Type: Article

References (56)

1. BCR-ABL protein. Proceedings National Academy of Sciences, 89, 1468-1472.
2. BCR-ABL protein by human T cells. Leukemia, 9, 1344-1348.
3. Yotnda P., Firat H., Garcia-Pons F., Garcia Z., Gourru G., Vernant J.P., Lemonnier F.A., Leblond V. and Langlade-Demoyen P. (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. Journal of Clinical Investigation, 101, 2290-2296.
4. Kessler J.H. et al manuscript in preparation.
5. Bocchia M., Wentworth P.A., Southwood S., Sidney J., McGraw K., Scheinberg D.A and Sette A. (1995) Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. BLOOD, 85, 2680-2684.
6. Greco G., Fruci D., Accapezzato D., Barnaba V., Nisini R., Alimena G., Montefusco E., Vigneti E., Butler R., Tanigaki N. and Tosi R. (1996) Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia, 10, 693-699.
7. Nieda M., Nicol A., KikuchiA., Kashiwase K., Taylor K., Suzuki K., Tadokoro K. and Juji T. (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia. BLOOD, 91, 977-983.
8. Buzyn A., Ostankovitch M., Zerbib A., Kemula M., Connan F., Varet B., Guillet J-G and Choppin J. (1997) Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. European Journal of Immunology, 27, 2066-2072.
9. Mannering S.I., McKenzie J.L., Fearnley D.B. and Hart D.N.J. (1997) HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. BLOOD, 90, 290-297.
10. 10) Ten Bosch G.J.A. et al unpublished observation.
11. Pawelec G., Max H., Halder Th., Bruserud Ø, Merl A., Da Silva P., and Kalbacher H. (1996) BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. BLOOD, 88, 2118-212.
12. Ten Bosch G.J.A., Joosten A.M., Kessler J.H., Melief C.J.M. and Leeksma O.C. (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunisation with a BCR-ABL breakpoint peptide. BLOOD, 88, 3522-3527.
13. Yasukawa M., Ohminami H., Kaneko S., Yakushijin Y., Nishimura Y., Inokuchi K., Miyakuni T., Nakao S., Kishi K., Kubonishi I., Dan K. and Fujita S. (1998) CD4+ Cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. BLOOD, 92, 3355-3361.
14. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S.Y., Sette A. and Scheinberg D.A. (1996) Specific human cellular immunity to ber-abl oncogene-derived peptides. BLOOD, 87, 3587-3592.
15. b2a2construct. BLOOD, 94, 1038-1045.
16. Papadopoulos K.P., Suciu-Foca N., Hesdorffer C.S., Tugulea S., Maffei A. and Harris P.E. (1997) Naturally processed tissue-and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. BLOOD, 90, 4938-4946.
17. Breitschopf K., Bengal E., Ziv T., Admon A. and Ciechanover A. (1998) A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. The Embo Journal, 17, 5964-5973.
18. Baumeister W., Walz J., Zühl F. and Seemüller E. (1998) The proteasome: paradigm of a self-compartmentalizing protease Cell, 92, 367-380.
19. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D. and Goldberg A. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78, 761-771.
20. Craiu A., Gaczynska M., Akopian T., Gramm C.F., Fenteany G., Goldberg A.L. and Rock K.L. (1997) Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. The Journal of Biological Chemistry, 272, 13437-13445.
21. Saglio G., Guerrasio A., Rosso C., Zaccaria A., Tassinari A., Serra A., Rege-Cambrin G., Mazza U, and Gavosto F. (1990) New type of BCR/ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. BLOOD, 76, 1819-1824.
22. Wada H., Mizutani S., Nishimura J., Usuki J., Kohsaki M., Komai M., Kaneko H., Sakamoto S., Delia D., Kanamura A. and Kakishita E. (1995) Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Research, 55, 3192-3196.
23. 1 translocation. Nature, 315, 758-761.
24. Shtivelman E., Lifshitz B., Gale R.P. and Canaani E. (1985) Fused transcript of abl and ber genes in chronic myelogenous leukemia. Nature, 315, 550-554.
25. Grosveld G., Verwoerd T., Van Agthove T., De Klein A., Ramachandran K.L., Stam K. and Groffen J. (1986) The chronic myelocytic leukemia cell line K562 contains a breakpoint in her and produces a chimeric bcr-c-abl transcript. Molecular Cell Biology, 6, 607-616.
26. Shtivelman E., Lifshitz B., Gale R.P., Roe B.A. and Canaani E. (1986) Alternative splicing of RNAs transcribed from the human abl gene and from the BCR-ABL fused gene. Cell, 47, 277-284.
27. How G.F., Lim L.C., Kulkarni S., Tan L.T., Tan P. and Cross N.C.P. (1999) Two patients with novel BCR/ABL fusion transcripts (e8a2 and e13a2) resulting from translocation breakpoints within BCR exons British Journal of Haematology, 105, 434-436.
28. Inukai T., Sugita K., Suzuki T., Ijima K., Goi K., Tezuka T., Kojika S., Hatakeyama K., Kagami K., Mori T., Okazaki T., Mizutani S. and Nakazawa S. (1993) A novel 203kD aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leukaemia. British Journal of Haematology, 85, 823-825.
29. Iwata S., Mizutani S., Nakazawa S. and Yata J-i. (1994) Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia, 8, 1696-1702.
30. Van der Plas D.C., Soekarman D., van Gent A.M., Grosveld G. and Hagemeijer A. (1991) bcr-abl mRNA lacking abl exon A2 detected by polymerase chain reaction in a chronic myelogenous leukemia. Leukemia, 5, 457-461.
31. Inokuchi K., Futaki M., Hanawa H., Tanosaki S., Jamaguchi H., Iwakiri R., Nomura T. and Dan K. (1997) Heterogeneous expression of BCR-ABL fusion mRNA in a patient with Philadelphia-chromosome-positive acute lymphoblastic leukaemia. British Journal of Haematology, 97, 837-840.
32. Hochhaus A., Reiter A., Reiter A., Skladny H., Melo J.V., Sick C., Berger U., Guo J.Q., Arlinghaus R.B., Hehlmann R. Goldman J.M. and Cross N.C.P. (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. BLOOD, 88, 2236-2240.
33. Martinelli G., Terragna C., Amabile M., Montefusco V., Testoni N., Ottaviani E., de Vivo A., Mianulli A., Saglio G.and Tura S. (1998) Translin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimaeric BCR-ABL transcript (e8-1NT-a2). BLOOD, 92, 93a.
34. Okamoto K., Karasawa M.. Sakai H., Ogura H., Morita K. and Naruse T. A novel acute lymphoid leukaemia typo BCR/ABL transcript in chronic myelogenous leukaemia. British Journal of Haematology, 96, 611-613.
35. Byrne J.L., Carter G.I., Davies J.M., Haynes A.P., Russell N.H. and Cross N.C.P. (1998) A novel BCR-ABL fusion gene (e2-la) in a patient with Philadelphia-positive chronic myelogenous leukemia and an aggressive clinical course. British Journal of Haematology, 103, 791-794.
36. Hermans A., Heisterkamp N., von Lindern M., van Baal S., Meijer D., van dor Plas D., Wiedemann L.M, Groffen J., Bootsma D. and Grosveld G. (1987) Unique fusion of her and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell, 51, 33-39.
37. Melo J.V., Myint H., Galton D.A. and Goldman J.M. (1994) P190BCR-ABL chronic mycloid leukaemia: the missing link with chronic myelomonocytic leukaemia?. Leukemia, 8, 208-211.
38. Saglio G., Pane F., Gottardi E., Frigeri F., Buonaiuto M.R., Guerrasio A., De Micheli D., Parziale A., Fornaci M.N., Martinelli G. and Salvatore F. (1996) Consistent amounts of acute leukemia-associated p190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. BLOOD, 87, 1075-1080.
39. Rhee F. van. Hochhaus A., Lin F., Melo J.V., Goldman J.M. and Cross N.C.P. (1996) P190BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemia. BLOOD, 87, 5213-5221.
40. Soekarman D. van Denderen J., Hoefsloot L., Morel M., Meeuwsen T., van Baal J., Hagemeijer A. and Grosveld G. (1990) Leukemia, 4, 397-403.
41. Mingari M.C., Moretta A. and Moretta L. (1998) Regulation of KIR expression in human T lymphocytes. A safety mechanism which may impair protective T cell responses. Immunology Today, 19, 153-157.
42. Sanchez M., Alfani M., Visconti G., Passurelli A.M., Migliacco A.R. and Migliacco G. (1998) Thymus-independent T-cell differentiation in vitro. British Journal of Haematology, 103, 1198-1205.
43. Pawelec G., Muller R., Rehbein A., Hahnel K. and Ziegler B.L. (1998) Extrathymic T cell differentiation in vitro from CD34+ stem cells Journal of Leukocyte Biology, 64, 733-739.
44. Hemmer B., Vergeli M., Gran B., Ling N., Conlon P., Pinilla C., Houghten R., McFarland H.F. and Martin R. (1998) Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. Journal nf Immunology, 160, 3631-363.
45. Apostopoulos V., Lofthouse S.A., Popovski V., Chelvanayagam G., Sandrin M. and McKenzie I.F.C. (1998) Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nature Biotechnology, 16, 276-280.
46. Ten Bosch G.J.A., Joosten A.M., Melief C.J.M. and Leeksma O.C. (1994) Cross reactivity of BCR-ABL peptide specific T cells with EBV transformed B cells. BLOOD, 84, 432a.
47. Biernaux C., Loos. M., Sels. A., Huez G. and Stryckmans (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. BLOOD, 86, 3118-3122.
48. Bose S., Deininger M., Gora-Tybor M., Goldman J. and Melo J.V. (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. BLOOD, 92, 3362-3367.
49. 1- cells from the same patient. BLOOD, 83, 3390-3402.
50. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmerman M. and Lydon N.B. (1996) Effects of a selective inhibitor of the Abelson tyrosine kinase on the growth of Bcr-Ahl positive cells. Nature Medicine, 2, 561-566.
51. Le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F. and Gambacorti-Passerini C. (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor Journal of the National Cancer Institute, 91, 163-168.
52. Albert M.L., Sauter B. and Bardwaj N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class-I-restricted CTLs. Nature, 392, 86-89.
53. Boussiotis V.K., Freeman G.J., Berezovskaya A., Barber D.L. and Nadler L.M. (1997) Maintenance of human T cell anergy: blocking of 1L-2 gene transcription by activated Rap1. SCIENCE, 278, 124-127.
54. Ten Bosch G.J.A., Kessler J.H., Blom J., Joosten A.M., Gambacorti-Passerini C., Melief C.J.M. and Leeksma O.C. (1998) BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. British Journal of Haematology, 103, 1109-1115.
55. Watai K., Tojo T., Nagamura -Inoue T., Tsujimura H., Nagamura F., Tani K. and Asano S. (1997) A new melanoma antigen. PRAME, is identified as a BCR-ABL-inducible gene in TF-1 cells. BLOOD, 90, 197a.
56. Chen C., Umezu K. and Kolodner R. (1998) Chromosomal rearrangements occur in s. cerevisiae rfal mutator mutants due to mutagenic lesions processed by double-strand-break repair. Molecular Cell, 2, 9-22.